aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Founded in 1997, Nephron Pharmaceuticals is dedicated to improving patient outcomes by providing high-quality, affordable generic respiratory medications and 503B drug compounding services. Their state-of-the-art, cGMP-compliant facility ensures the production of sterile medications, catering primarily to healthcare providers and institutions in need of reliable pharmaceutical outsourcing solutions.
Notable figures associated with Nephron include CEO Lou Kennedy, who has been instrumental in driving the company's growth and innovation. The company has achieved significant milestones, such as becoming a global leader in its market segment and expanding its manufacturing capabilities. Nephron's impact is evident in its commitment to safety, quality, and community engagement, solidifying its reputation as a trusted partner in the pharmaceutical industry.
Operating Status
Active
Ownership Type(s)
Private
Main Product(s)
Medications, Compounding
Technology
Pharmaceuticals
Tags
Biotech
Model Types
Manufacturing
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise, Government
Geographic Exposure
Global
When was Nephron Pharmaceuticals founded?
Nephron Pharmaceuticals was founded in 1937.
Where is Nephron Pharmaceuticals’s headquarters located?
Nephron Pharmaceuticals’s headquarters is located in Orlando, FL, US.
When was Nephron Pharmaceuticals’s last funding round?
Nephron Pharmaceuticals’s most recent funding round was for $350M (USD) in September 2023.
How many employees does Nephron Pharmaceuticals have?
Nephron Pharmaceuticals has 816 employees as of Feb 4, 2024.
How much has Nephron Pharmaceuticals raised to-date?
As of July 05, 2023, Nephron Pharmaceuticals has raised a total of $425M (USD) since Sep 15, 2023.
Add Comparison
Total Raised to Date
$425M
USD
Last Update Sep 15, 2023
Last Deal Details
$350M
USD
Sep 15, 2023
Private Equity
Total Employees Over Time
816
As of Feb 2024
Nephron Pharmaceuticals Address
3330 Vineland Road
Orlando,
Florida
32811
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts